Bionomics (NASDAQ:BNOX) Given Outperform Rating at William Blair

William Blair restated their outperform rating on shares of Bionomics (NASDAQ:BNOX) in a research note released on Friday morning,RTT News reports.

Separately, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Bionomics in a report on Thursday, August 1st.

Bionomics Price Performance

Shares of NASDAQ BNOX opened at $0.29 on Friday. The business has a 50 day simple moving average of $0.40 and a 200 day simple moving average of $0.63. Bionomics has a 52 week low of $0.18 and a 52 week high of $2.19.

Institutional Investors Weigh In On Bionomics

A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC acquired a new position in shares of Bionomics Limited (NASDAQ:BNOX) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 15.03% of Bionomics at the end of the most recent quarter. 15.90% of the stock is owned by hedge funds and other institutional investors.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.